The Grand Global Health Convergence
For starters, improved access to contraception would prevent an estimated one-third of all maternal deaths, and would have a particularly large impact among those facing the highest risk. These include 15-19-year-old women in poor countries, who currently have the least access to contraception, and women who have multiple pregnancies in quick succession, by allowing them to space out their pregnancies. By reducing the rate of unwanted pregnancies, family planning also decreases the number of deaths from unsafe abortions.
This is not only good for mothers. Reducing high-risk pregnancies, curbing unwanted pregnancies, and spacing out births have been shown to decrease newborn and child death rates. The Guttmacher Institute estimates that fully meeting women’s need for contraception would prevent 600,000 newborn deaths and 500,000 child deaths annually.
Moreover, cutting birth rates, which are very high in many LMICs, would help to reduce the strain on these countries’ health-care systems by diminishing the costs of maternal and newborn care and immunization. At the same time, it would facilitate social change that fuels increased productivity and output. According to a study coordinated by the World Health Organization, the economic return from scaling up contraception in 27 countries with very high birth rates, such as Afghanistan and Chad, would exceed 8% of GDP from now until 2035.
So, how much would it cost to ensure universal access to modern medicine and health services? Global Health 2035 puts the total at an additional $70 billion dollars annually, with $1 billion of this increase allocated to family planning alone.
But most of the costs can ultimately be covered by LMICs themselves. In fact, the total bill for global health convergence amounts to less than 1% of the additional GDP that these countries are expected to generate in the next two decades. In other words, public investment of less than 1% of GDP could avert a massive ten million deaths each year.
Innovative partnerships aimed at reducing costs can diminish this burden even more. A group of donor governments, foundations, the United Nations, and private-sector actors recently came together to reduce the price of a long-lasting contraceptive implant (Levonorgestrel) from $18 to $8.50 per unit in more than 50 LMICs.
The international community must play a major role in achieving convergence. Specifically, it must increase investment in research and development for the diseases that affect the poor, like childhood pneumonia and diarrhea, which kill around two million children every year. And direct financial assistance to LMICs – for example, to fund family-planning programs and combat malaria and HIV/AIDS – will be required for years to come.
The opportunity to achieve a grand convergence in global health outcomes is within reach. We need only to convince ourselves to grasp it.
Helen Saxenian, Gavin Yamey